Literature DB >> 7802767

Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases.

G Enders1, E Miller, J Cradock-Watson, I Bolley, M Ridehalgh.   

Abstract

In a joint prospective study in Germany and the United Kingdom between 1980 and 1993, 1373 women who had varicella and 366 who had herpes zoster during the first 36 weeks of gestation were followed up. 9 cases of congenital varicella syndrome were identified, all occurring after maternal varicella during the first 20 weeks of gestation. The highest risk (2.0%) was observed between 13-20 weeks gestation, with 7 affected infants identified among 351 pregnancies (95% CI of risk 0.8-4.1%). Only 2 cases of congenital varicella syndrome were identified among 472 pregnancies in which maternal varicella occurred before 13 weeks (observed risk 0.4%, 95% CI 0.05-1.5%). Herpes zoster in infancy was reported in 10 children whose mothers had had varicella in pregnancy. No infants with clinical evidence of intrauterine infection were born to the 366 women with herpes zoster in pregnancy (upper 95% confidence limit of estimated risk 1.0%). Varicella-zoster-specific IgM antibody was found at birth in 4 of 16 (25%) infants with clinical manifestations of intrauterine infection and persistent specific IgG antibody in 5 of 7 infants tested. The corresponding rates in asymptomatic infants whose mothers had varicella were 12% (76/615) and 7% (22/335) respectively. No serological evidence of intrauterine infection was found in infants who mothers had herpes zoster in pregnancy. In 97 pregnant women, varicella occurred after post-exposure prophylaxis with anti-varicella-zoster immunoglobulin. No cases of congenital varicella syndrome or zoster in infancy occurred in this group. Our estimates provide a sound basis for counselling women with varicella in pregnancy. Although the risk of congenital varicella syndrome is small, the outcome for the affected infant is so serious that a reliable method of prenatal diagnosis would be valuable. In the long term, prevention of maternal varicella would be an option if a safe and effective vaccine were to become routinely available.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7802767     DOI: 10.1016/s0140-6736(94)92943-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  78 in total

Review 1.  Fetal pharmacotherapy.

Authors:  Gideon Koren; Gil Klinger; Arne Ohlsson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  The incidence of chickenpox in the community. Lessons for disease surveillance in sentinel practice networks.

Authors:  D M Fleming; F G Schellevis; I Falcao; T V Alonso; M L Padilla
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

3.  Incidence of vesicobullous and erosive disorders of neonates.

Authors:  Goyal Tarang; Varshney Anupam
Journal:  J Dermatol Case Rep       Date:  2011-12-12

4.  Risk of varicella infection during late pregnancy.

Authors:  Gideon Koren
Journal:  Can Fam Physician       Date:  2003-11       Impact factor: 3.275

5.  Prenatal screening: invasive diagnostic approaches.

Authors:  Claude d'Ercole; Raha Shojai; Raoul Desbriere; Cécile Chau; Florence Bretelle; Laurence Piéchon; Léon Boubli
Journal:  Childs Nerv Syst       Date:  2003-08-08       Impact factor: 1.475

Review 6.  [Skin infections in pregnancy].

Authors:  R R Müllegger; M Glatz
Journal:  Hautarzt       Date:  2010-12       Impact factor: 0.751

Review 7.  [Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics].

Authors:  Miriam Wittek; Hans Wilhelm Doerr; Regina Allwinn
Journal:  Med Klin (Munich)       Date:  2010-05-26

8.  Primary varicella in an immunocompetent adult.

Authors:  Izikson Leonid; Lilly Evelyn
Journal:  J Clin Aesthet Dermatol       Date:  2009-08

Review 9.  Best practice in primary care pathology: review 6.

Authors:  W S A Smellie; J Forth; J J Coleman; W Irvine; P C Dore; G Handley; D G Williams; P J Galloway; K G Kerr; R Herriot; G P Spickett; T M Reynolds
Journal:  J Clin Pathol       Date:  2006-07-05       Impact factor: 3.411

10.  The varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA.

Authors:  Melissa A Visalli; Brittany L House; Anca Selariu; Hua Zhu; Robert J Visalli
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.